Trial Profile
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Hepatic encephalopathy; Hyperammonaemia
- Focus Adverse reactions
- Sponsors Hyperion Therapeutics
- 27 Jun 2014 New trial record